Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $2.7 million.

  • Whitehawk Therapeutics' Share-based Compensation rose 6.30% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 22.79%. This contributed to the annual value of $10.8 million for FY2024, which is 9.33% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Share-based Compensation stood at $2.7 million for Q3 2025, which was down 11.95% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Share-based Compensation ranged from a high of $3.6 million in Q1 2024 and a low of $36,000 during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $2.8 million (2024), whereas its average is $2.8 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Share-based Compensation slumped by 89.01% in 2021, and later spiked by 5,630.77% in 2022.
  • Whitehawk Therapeutics' Share-based Compensation (Quarterly) stood at $1.4 million in 2021, then skyrocketed by 107.52% to $2.9 million in 2022, then increased by 8.40% to $3.1 million in 2023, then plummeted by 40.41% to $1.9 million in 2024, then climbed by 6.30% to $2.7 million in 2025.
  • Its Share-based Compensation stands at $2.7 million for Q3 2025, versus $3.1 million for Q2 2025 and $1.7 million for Q1 2025.